Table 2.
Retrospective studies of CMV reactivation in multiple myeloma.
| Reference | Chemotherapy, total number in study |
Regular CMV exam | CMV infection | CMV disease | Median amount of viremia | Antiviral treatment | Resume of chemotherapy |
|---|---|---|---|---|---|---|---|
| Kikuchi et al. [11] | Ide-cel, 53 | Weekly | 38.9% (20/53) | 4 retinitis | ND | 8/20 | ND |
| Pei et al. [26] | Teclistamab, 23 | ND | 52.2% (12/23) | 1 enterocolitis | DNA 2295 IU/mL (653-165000) |
11/12 | 11/12 |
| Baneman et al. [27] | CAR-T, 6 BsAb, 5 mAb, 11 |
Biweekly | 64% (14/22) | No | DNA 34.5 IU/mL (34.5-14100) |
1/14 | ND |
| De Novellis et al. [5] | Dara, 51 Non-Dara 50 |
ND | Dara 33% (17/51) non-Dara 4% (2/51) | 1 pneumonia | DNA 192 UI/mL (34.5-14100) |
Dara 7/51 non-Dara 0/51 | ND |
| Matsunaga et al. [6] | Dara, 154 | Partial | 19% (29/154) | 1 hepatitis, 1 retinitis 1 gastroenteritis |
Antigenemia 5 (2–27) cells/slide |
25/29 | 7 discontinued |
| Kikuchi et al. [7] | Dara, 53 | Partial | 17% (9/53) | 1 pneumonia | Antigenemia 4 (1–117) cells/slide |
1/9 | ND |
| Li et al. [8] | Dara, 53 Non-Dara, 78 |
Yes | Dara 17% (9/53) non-Dara 3% (2/78) | None | DNA 4360 cp/mL (1200–13700) |
7/11 | ND |
| Tabata et al. [9] | Dara, 15 | Yes (1-2 times/wk) | 73% (11/15) | None | Antigenemia 13 (2–104) cells/slide |
8/11 | ND |
| Nakagawa et al. [10] | Dara, 13 | No | 38% (5/13) | None | Antigenemia 12 (1–71) |
5/5 | 1 postponed |
| Kikuchi et al. [28] | Elo, 85 | ND | 19% (16/85) | 1 retinitis | ND | 5/16 | ND |
| Sharpley et al. [29] | Bor, 57 | Yes (biweekly) | 39% (12/31) | None | Median; ND DNA > 7500 cp/mL (5/12) |
5/12 | ND |
| Massoud et al. [25] | Auto-HSCT, 132 | Yes (weekly) | 22% (29/132) | 3 enteritis | Median; ND DNA > 1000 cp/mL (11/29) |
22/29 | ND |
| Hasegawa et al. [24] | 120 | No | 20% (24/120) | 2 enteritis 1 gastritis |
Antigenemia 2 (1–196) cells/slide |
13/24 | ND |
Note: C: anterior chamber of eye; Auto-HSCT: autologous hematopoietic stem cell transplantation; CAR-T: chimeric antigen receptor T cell therapy; CMV: cytomegalovirus; Dara: daratumumab; DCd: daratumumab/cyclophosphamide; DRd: daratumumab/lenalidomide/dexamethasone; DVd, daratumumab/bortezomib/dexamethasone; GCV, ganciclovir; KPd, carfilzomib/pomalidomide/dexamethasone; Len, lenalidomide; mo, month; Rd, lenalidomide/dexamethasone; Ven, venetoclax; VGCV, valganciclovir; VRd, bortezomib/lenalidomide/dexamethasone; wk, weeks.
Abbreviations: IVT, intravitreal therapy; ND, not described; PD, progressive disease.